PXMD vs. ERNA, VAXX, NCNA, ADXN, OGEN, GRAY, SHPH, ATHE, ABVC, and CANF
Should you be buying PaxMedica stock or one of its competitors? The main competitors of PaxMedica include Eterna Therapeutics (ERNA), Vaxxinity (VAXX), NuCana (NCNA), Addex Therapeutics (ADXN), Oragenics (OGEN), Graybug Vision (GRAY), Shuttle Pharmaceuticals (SHPH), Alterity Therapeutics (ATHE), ABVC BioPharma (ABVC), and Can-Fite BioPharma (CANF). These companies are all part of the "pharmaceutical preparations" industry.
Eterna Therapeutics (NASDAQ:ERNA) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation, profitability and community ranking.
PaxMedica received 1 more outperform votes than Eterna Therapeutics when rated by MarketBeat users.
PaxMedica has a consensus target price of $3.00, indicating a potential upside of 808.54%. Given Eterna Therapeutics' higher probable upside, analysts plainly believe PaxMedica is more favorable than Eterna Therapeutics.
In the previous week, Eterna Therapeutics had 2 more articles in the media than PaxMedica. MarketBeat recorded 2 mentions for Eterna Therapeutics and 0 mentions for PaxMedica. PaxMedica's average media sentiment score of 0.43 beat Eterna Therapeutics' score of 0.00 indicating that Eterna Therapeutics is being referred to more favorably in the media.
70.6% of Eterna Therapeutics shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 35.4% of Eterna Therapeutics shares are held by insiders. Comparatively, 1.0% of PaxMedica shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Eterna Therapeutics has a beta of 4.31, suggesting that its stock price is 331% more volatile than the S&P 500. Comparatively, PaxMedica has a beta of -0.17, suggesting that its stock price is 117% less volatile than the S&P 500.
PaxMedica has lower revenue, but higher earnings than Eterna Therapeutics.
Eterna Therapeutics' return on equity of -1,151.77% beat PaxMedica's return on equity.
Summary
Eterna Therapeutics beats PaxMedica on 7 of the 12 factors compared between the two stocks.
Get PaxMedica News Delivered to You Automatically
Sign up to receive the latest news and ratings for PXMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PaxMedica Competitors List
Related Companies and Tools
